[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cardiovascular-abnormalities\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cardiovascular-abnormalities":33},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,54,82,124,155,176,210],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":53},"100289553","mayo-avc-registry-and-biobank-100289553",false,"NCT03049254","Mayo AVC Registry and Biobank","Identification of Novel Genetic Variants and Biomarkers of Disease Progression in Arrhythmogenic Cardiomyopathy","Inclusion Criteria:\n\n* Patients with a diagnosis of a non-MI SCA who survived\n* Patients with a non-MI SCD\n* Patient with a SCA associated with seizures, epilepsy, syncope, drowning and near-drowning, where a cardiomyopathy is suspected\n* Family member of a patient diagnosed with primary cardiomyopathy (including HCM, idiopathic DCM, AVC)\n\nExclusion Criteria:\n\n* Patients with a clear, unambiguous known cause of SCA or SCD such as myocardial infarction or heart failure secondary to ischemic heart disease\n* Significant coronary artery disease (Epicardial coronary artery stenosis \\>50%) which can explain degree of LV dysfunction\n* Those unwilling to provide written consent or assent",true,"ALL",{"count":19,"type":20},1000,"ESTIMATED","OBSERVATIONAL","Arrhythmogenic ventricular cardiomyopathy (AVC) is a genetic condition which affects the heart and can lead to heart failure and rhythm problems, of which, sudden cardiac arrest or death is the most tragic and dangerous. Diagnosis and screening of blood-relatives is very difficult as the disease process can be subtle, but sufficient enough, so that the first event is sudden death.\n\nThe Mayo Clinic AVC Registry is a collaboration between Mayo Clinic, Rochester, USA and Papworth Hospital, Cambridge University Hospitals, Cambridge, UK. The investigators aim to enroll patients with a history of AVC or sudden cardiac death which may be due to AVC, from the US and UK. Family members who are blood-relatives will also be invited, including those who do not have the condition. Data collected include symptoms, ECG, echocardiographic, MRI, Holter, loop recorder, biopsies, exercise stress testing, blood, buccal and saliva samples.\n\nObjectives of the study:\n\n1. Discover new genes or altered genes (variants) which cause AVC\n2. Identify biomarkers which predict (2a) disease onset, (2b) disease progression, (2c) and the likelihood of arrhythmia (ventricular, supra-ventricular and atrial fibrillation)\n3. Correlate genotype with phenotype in confirmed cases of AVC followed longitudinally using clinical, electrocardiographic and imaging data.\n4. Characterize desmosomal changes in buccal mucosal cells with genotype and validate with gold-standard endomyocardial biopsies",[24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40],"Arrhythmogenic Right Ventricular Cardiomyopathy","Cardiomyopathies","Heart Diseases","Cardiovascular Diseases","Sudden Cardiac Arrest","Sudden Cardiac Death","Arrhythmogenic Right Ventricular Dysplasia","Arrhythmogenic Ventricular Cardiomyopathy","Familial Dilated Cardiomyopathy","Cardiovascular Abnormalities","Sarcoidosis","Cardiac Arrhythmia","Cardiac Sarcoidosis","Myocarditis","Inflammatory Cardiomyopathy","Ventricular Tachycardia","Right Ventricular Outflow Tract Ventricular Tachycardia","RECRUITING","2026-04-22",{"date":44,"type":45},"2026-04-27","ACTUAL",{"date":47,"type":45},"2018-02-09",{"date":49,"type":20},"2027-03",{"name":51,"class":52},"Mayo Clinic","OTHER",2,{"id":55,"slug":56,"hasResults":11,"nctId":57,"briefTitle":58,"officialTitle":58,"acronym":4,"eligibilityCriteria":59,"healthyVolunteers":16,"sex":17,"minAge":60,"maxAge":61,"enrollmentInfo":62,"targetDuration":4,"studyType":64,"phases":65,"briefSummary":68,"conditions":69,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":81},"100623714","phase-1-clinical-application-of-al18f-nota-fapi-04-petct-or-petmri-imaging-in-malignant-tumorcardiovascular-or-immune-disease-100623714","NCT07400224","Clinical Application of Al18F-NOTA-FAPI-04 PET\u002FCT or PET\u002FMRI Imaging in Malignant Tumor,Cardiovascular or Immune Disease","Inclusion Criteria:\n\n* a. Age 18 years old or above, gender not restricted. b. Have undergone a health check-up within the last 3 months (at least completed chest X-ray \u002F chest CT and abdominal B-ultrasound and other examinations), and no major diseases were found.\n\nExclusion Criteria:\n\n* As this study involves certain radiation exposure, patients who have had frequent radiation exposure due to clinical needs (those who have undergone a CT or PET\u002FCT examination once within 3 months or 1 month respectively) are not included in the study.","18 Years","88 Years",{"count":63,"type":20},600,"INTERVENTIONAL",[66,67],"PHASE1","PHASE2","This prospective, single-center study investigates the biodistribution, dosimetry, safety, diagnostic performance of Al18F-NOTA-FAPI PET imaging in patients with malignant tumor,cardiovascular or immune disease. And evaluates the potential of Al18F-NOTA-FAPI PET imaging in Clinical treatment strategy guidance.",[70,33,71],"Hyperthyroidism, Autoimmune","Malignant Tumor","2026-02-03",{"date":74,"type":45},"2026-02-10",{"date":76,"type":45},"2022-05-10",{"date":78,"type":20},"2028-12-31",{"name":80,"class":52},"Peking Union Medical College Hospital",1,{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":4,"eligibilityCriteria":88,"healthyVolunteers":16,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":89,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":91,"conditions":92,"keywords":105,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":81},"100615334","long-term-follow-up-of-the-offspring-born-to-mothers-with-a-solid-organ-transplant-transplantlines-next-generation-100615334","NCT07291258","Long-term Follow-up of the Offspring Born to Mothers With a Solid Organ Transplant, Transplantlines Next Generation","Long-term Follow-up of the Offspring Born to Mothers With a Solid Organ Transplant","Inclusion Criteria:\n\n* Mother with a KTx, LiTx, PTx (including pancreas islet transplantation), HTx or LuTx before pregnancy (including mothers with multiple transplantation types)\n* Age ≥16 years for offspring born to mother with a KTx or LiTx\n\nExclusion Criteria:\n\n* No informed consent\n* Non Dutch or English speaking",{"count":90,"type":20},200,"Background Pregnancy after all types of solid organ transplantation (SOT) is possible, although these have higher risk of pregnancy complications for mother and child, such as preeclampsia and preterm birth. Thus, the development of the unborn child seems to be affected by the transplant and its consequences such as the immunosuppressive medication use. Worldwide data regarding follow-up after birth is scarce. The very limited existing data existing only in young children are reassuring. However, the investigators hypothesize that there are health risks for the children. Given the side effects of the immunosuppressive medication on patients and limited knowledge from animal studies, the investigators particularly expect cardiovascular effects such as hypertension and kidney damage. These develop over a long time-period and lead late to symptoms.\n\nAims Aim of this study is to gain more insight into the overall health of offspring born after SOT. Primary aim is to assess the cardiovascular health and the presence of kidney disease, and compare these with reference values from the general population or birth cohorts. Secondary aims are the immunological status including the microbiome of the child given the maternal immunosuppressive medication use, and the overall development of the offspring, including qualitative research regarding the quality of life. Third aim is to assess if there are differences in health between offspring born to mothers with a kidney, liver, pancreas (including pancreas islet), heart and lung transplantation (KTx, LiTx, PTx, HTx, LuTx resp.). The investigators also want to establish a biobank for later follow-up research.\n\nStudy design This will be a cross-sectional monocenter cohort study. All offspring ≥16 years of age born after KTx or LiTx and all offspring born at any age after PTx, HTx and LuTx in the Netherlands will be eligible for inclusion. The investigators estimate that there will be about 150(-220) participants. Before the study visit, participants will be asked to complete a questionnaire. Participants will be invited for a one-time study visit consisting of physical tests (including ultrasound of the kidneys and a 24-hour ambulatory blood pressure measurement) and biological sample (urine, blood and feces) collection, including sample collection for biobanking. Information about the growth and development of the offspring and, if present, diseases and medication use will be collected from the medical files of the general practitioner and pharmacy (LSP) and from data from the youth healthcare check-ups. As a control group pseudoanonymized data from the Lifelines cohort will be used.\n\nDeliverables To the best of our knowledge, this will be the first study worldwide that will gather and analyze detailed information about the cardiovascular, kidney and immunological health at a later age (≥16 years) in the offspring born to mothers after KTx, LiTx, PTx, HTx and LuTx. This information will be important for the preconceptional counseling of families with a pregnancy wish after transplantation and thereby contribute to the health of women with a SOT. Next to that, find adverse effects of the pregnancy after transplantation on the offspring are found, the investigators expect there will be modifiable factors and\u002For early screening\u002Finterventions that can reduce these risks and thereby contribute to the health of the offspring.",[93,94,95,96,97,98,99,100,101,102,33,103,104],"Solid Organ Transplantation","Pregnancy","Long-term Follow-up","Kidney Transplant","Liver Transplant","Pancreas Transplant","Heart Transplantation","Lung Transplantation","Offspring, Adult","Children","Kidney Disease","Quality of Life",[106,94,107,108,109,110,111,112,113,114],"Solid organ transplantation","Offspring","Long-term follow-up","kidney transplantation","liver transplantation","pancreas transplantation","pancreas islet transplantation","Heart transplantation","lung transplantation","2025-12-04",{"date":117,"type":45},"2025-12-18",{"date":119,"type":45},"2025-10-15",{"date":121,"type":20},"2028-06",{"name":123,"class":52},"University Medical Center Groningen",{"id":125,"slug":126,"hasResults":11,"nctId":127,"briefTitle":128,"officialTitle":129,"acronym":130,"eligibilityCriteria":131,"healthyVolunteers":11,"sex":17,"minAge":60,"maxAge":4,"enrollmentInfo":132,"targetDuration":4,"studyType":64,"phases":134,"briefSummary":136,"conditions":137,"keywords":139,"overallStatus":145,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":147,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":153,"locationsCount":4},"100606717","evaluation-of-clinical-intelligence-support-to-reduce-errors-in-normal-ecgs-100606717","NCT07179185","Evaluation of Clinical Intelligence Support to Reduce Errors in Normal ECGs","PRECISE-ECG: Prospective Randomized Evaluation of Clinical Intelligence Support to Reduce Errors in Normal ECGs","PRECISE-ECG","Inclusion Criteria:\n\n* ECGs performed routinely by the Rede de Telemedicina de Minas Gerais (RTMG)\n\nExclusion Criteria:\n\n* ECGs from patients younger than 18 years",{"count":133,"type":20},710,[135],"NA","This study will evaluate the performance of specialist physicians in interpreting normal electrocardiograms (ECGs) with and without the assistance of an artificial intelligence (AI) neural network. The primary aim is to determine whether AI support affects the rate of false-positive interpretations of normal tracings. Secondary aims include evaluating the time required for interpretation, the sensitivity for detecting abnormalities, and the effect on false positives in ECGs with major abnormalities according to the Minnesota Code system. All ECGs in the sample will be reviewed by a panel of three specialists, to determine the reference classification.",[138,33],"Electrocardiogram",[140,141,142,143,144],"artificial intelligence","electrocardiography","diagnostic methods","telemedicine","normal electrocardiogram","NOT_YET_RECRUITING","2025-09-16",{"date":148,"type":45},"2025-09-22",{"date":150,"type":20},"2025-10-01",{"date":152,"type":20},"2025-11",{"name":154,"class":52},"Federal University of Minas Gerais",{"id":156,"slug":157,"hasResults":11,"nctId":158,"briefTitle":159,"officialTitle":160,"acronym":4,"eligibilityCriteria":161,"healthyVolunteers":11,"sex":17,"minAge":60,"maxAge":162,"enrollmentInfo":163,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":165,"conditions":166,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":168,"lastUpdatePostDateStruct":169,"startDateStruct":171,"completionDateStruct":172,"leadSponsor":174,"locationsCount":81},"100597670","exercise-addiction-and-health-risks-in-gym-users-100597670","NCT07061509","Exercise Addiction and Health Risks in Gym Users","Musculoskeletal and Cardiovascular Effects of Exercise Addiction in Recreational Bodybuilders","Inclusion Criteria:\n\n* Aged ≥18 years\n* Member of a fitness center\n* Regular physical activity (≥3 times per week)\n* Voluntary participation with informed consent\n\nExclusion Criteria:\n\n* Diagnosed psychiatric illness\n* Professional or elite athletes\n* Incomplete questionnaire data","85 Years",{"count":164,"type":20},32,"This observational study aims to investigate the prevalence of musculoskeletal injuries and cardiovascular risk factors among individuals with and without exercise addiction. Adult recreational gym users who have been engaging in resistance training for at least six months will be included. Participants will be divided into two groups based on their exercise dependence levels, and outcomes such as musculoskeletal symptoms, anabolic substance use, and cardiovascular risk scores will be compared between groups.",[167,33],"Exercise Addiction","2025-07-29",{"date":170,"type":45},"2025-07-30",{"date":168,"type":45},{"date":173,"type":20},"2026-07-20",{"name":175,"class":52},"Saglik Bilimleri Universitesi",{"id":177,"slug":178,"hasResults":11,"nctId":179,"briefTitle":180,"officialTitle":181,"acronym":182,"eligibilityCriteria":183,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":184,"targetDuration":4,"studyType":64,"phases":186,"briefSummary":187,"conditions":188,"keywords":197,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":201,"lastUpdatePostDateStruct":202,"startDateStruct":204,"completionDateStruct":206,"leadSponsor":208,"locationsCount":81},"100398402","phase-2-two-year-study-of-the-safety-and-efficacy-of-the-second-generation-tissue-engineered-vascular-grafts-100398402","NCT04467671","Two-Year Study of the Safety and Efficacy of the Second-Generation Tissue Engineered Vascular Grafts","Prospective, Open-labeled, Single-arm Clinical Trial to Evaluate the Safety and Efficacy of the Second-generation Tissue Engineered Vascular Graft as Vascular Conduits for Extracardiac Total Cavopulmonary Connection.","TEVG-2","Inclusion Criteria:\n\n* Patients will be eligible for inclusion in the study if they meet all of the following criteria.\n\n  1. Patient must be a candidate to undergo an extracardiac total cavopulmonary connection.\n  2. Patient and\u002For legal guardian must voluntarily provide informed consent\u002Fassent for participation in the study.\n\nExclusion Criteria:\n\n* Patients will be excluded from participation in the study if they meet any of the following criteria.\n\n  1. Patient has an urgent\u002Femergent operative status.\n  2. Patient has acute renal failure or renal insufficiency in the opinion of the investigator\n  3. Patient requires a graft less than 12 mm or greater than 24 mm in diameter.\n  4. Patient has a pacemaker.\n  5. Patient has pulmonary vascular resistance greater than 4 um2 (u=Wood's units)\n  6. Patient has abnormal venous drainage (interrupted inferior vena cava \\[IVC\\]).\n  7. Patient presents with significant atrio-ventricular valve regurgitation that in the opinion of the investigator, makes them ineligible.\n  8. Patient has a history of another condition or significant medical problem that, in the opinion of the investigator, precludes compliance with protocol-specified procedures.\n  9. Patients taking any medications that in the opinion of the Investigator could interfere with the TEVG, including bisphosphonates (i.e. Clodronate or Zoledronate).\n  10. Patient or parent\u002Flegal guardian is, in the opinion of the investigator, unable to comply with protocol evaluations.\n  11. Preoperative hemoglobin \\\u003C11.0 mg\u002FdL at time of patient's pre-admission testing.",{"count":185,"type":20},24,[67],"A single arm clinical trial evaluating the safety and efficacy of the second generation TEVG as vascular conduits for extracardiac total cavopulmonary connection.",[189,190,191,192,193,194,195,196,33,27,26],"HLH - Hypoplastic Left Heart Syndrome","DORV","DILV - Double Inlet Left Ventricle","Mitral Atresia","Tricuspid Atresia","Unbalanced AV Canal","Single-ventricle","Heart Defects, Congenital",[198,199,200],"Fontan","TEVG","Tissue Engineered Vascular Graft","2025-06-24",{"date":203,"type":45},"2025-06-27",{"date":205,"type":45},"2020-07-15",{"date":207,"type":20},"2027-08",{"name":209,"class":52},"Nationwide Children's Hospital",{"id":211,"slug":212,"hasResults":11,"nctId":213,"briefTitle":214,"officialTitle":214,"acronym":215,"eligibilityCriteria":216,"healthyVolunteers":16,"sex":217,"minAge":218,"maxAge":60,"enrollmentInfo":219,"targetDuration":4,"studyType":64,"phases":221,"briefSummary":222,"conditions":223,"keywords":4,"overallStatus":145,"whyStopped":4,"lastUpdateSubmitDate":226,"lastUpdatePostDateStruct":227,"startDateStruct":229,"completionDateStruct":231,"leadSponsor":233,"locationsCount":4},"100550768","cardiovascular-and-endocrine-response-to-muscular-training-program-of-young-soccer-players-aged-14-18-years-100550768","NCT06451367","Cardiovascular and Endocrine Response to Muscular Training Program of Young Soccer Players Aged 14-18 Years","YoungSoccer","Inclusion Criteria:\n\n* Engaging in a football training program.\n* No history of injuries in the last 6 months requiring surgical intervention.\n* No intake of anabolic supplements.\n* Age 14-18 years old.\n* Normal BMI (18.5 - 24.9 kg\u002Fm²).\n\nParents and participants must consent to receive all pertinent information discovered during the study, such as potential cardiovascular diseases or hormonal disorders.\n\nParticipants must also consent to the sharing of certain private information with their parents or legal guardians. This includes information regarding cannabis use, as well as the consumption of anabolic steroids and other controlled substances. This additional consent ensures transparency and openness in sharing relevant health-related information with parents or legal guardians, particularly for participants under 18 years of age.\n\nFor participants under the age of 18, parental consent or consent from a legal guardian is mandatory in addition to the participant's consent. This ensures that minors have parental approval to take part in the study.\n\nAll participants, regardless of age, must provide their voluntary consent to participate in the study. For participants under the age of 18, consent from one of their parents or legal guardians is also required in addition to the participant's consent.\n\nExclusion Criteria:\n\n* Engaging in other supplemental individual exercise programs.\n* Being a smoker (\\>1 cigarette\u002Fweek).\n* Using any medication at the time of testing.\n* Having any disease.","MALE","14 Years",{"count":220,"type":20},30,[135],"This study focuses on understanding the cardiovascular and endocrine responses of young soccer players aged 14 to 18 years to a muscular training program. Adolescence is a critical period for physiological development, and investigating these responses can provide insights crucial for athletic performance and overall health. The benefits include promoting overall health, reducing injury risk, and enhancing scientific knowledge. However, intensive training programs may lead to overtraining and potential negative health outcomes if not carefully monitored. The study aims to assess whether additional neuromuscular development over 12 weeks can enhance players' physical fitness and hormonal changes. By examining these outcomes, the study seeks to inform evidence-based training protocols for optimizing adolescent athletes' health and performance in soccer. The study design involves a prospective single-center randomized cohort to investigate these responses comprehensively.",[224,225,33],"Sport Injury","Hormone Disturbance","2024-06-19",{"date":228,"type":45},"2024-06-24",{"date":230,"type":20},"2024-06-28",{"date":232,"type":20},"2024-12-31",{"name":234,"class":52},"Hôpital Fribourgeois"]